HC Wainwright reissued their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK – Free Report) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock. HC Wainwright also issued estimates for Outlook Therapeutics’ FY2027 earnings at $1.17 EPS and FY2028 earnings at $3.14 EPS.
Outlook Therapeutics Stock Performance
NASDAQ OTLK traded up $0.12 on Thursday, hitting $7.80. 167,899 shares of the stock traded hands, compared to its average volume of 379,230. The business’s fifty day moving average is $7.67 and its two-hundred day moving average is $8.06. Outlook Therapeutics has a 12 month low of $4.00 and a 12 month high of $29.20. The firm has a market capitalization of $182.60 million, a price-to-earnings ratio of -0.69 and a beta of 0.71.
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.67). Analysts expect that Outlook Therapeutics will post -4.08 EPS for the current fiscal year.
Institutional Investors Weigh In On Outlook Therapeutics
About Outlook Therapeutics
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
See Also
- Five stocks we like better than Outlook Therapeutics
- What is the Euro STOXX 50 Index?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- What is a Secondary Public Offering? What Investors Need to Know
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Using the MarketBeat Dividend Tax Calculator
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.